evidence/gaps
Cochrane · systematic review · CD013845

Memantine for autism spectrum disorder

Brignell, A, Marraffa, C, Williams, K, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library

Developmental, Psychosocial and Learning ProblemsAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 14.3%Low 6 · 85.7%Moderate 0 · 0%High 0 · 0%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Memantine versus placebo for autism

Population: children/adolescents diagnosed with ASD
7 questions
OutcomeEffectEvidenceStatus / GRADE
Core symptoms of autism
Memantine vs placebo
no estimate extracted2 studies · 181 participantsVery low
Downgraded: risk of bias, imprecision, inconsistency
Adverse effects Assessed by the study authors as those that were sufficient to discontinue treatment
Memantine vs placebo
OR 0.64 [0.17, 2.39]2 studies · 144 participantsLow
Downgraded: risk of bias, imprecision
Language
Memantine vs placebo
no estimate extracted2 studies · 144 participantsLow
Downgraded: risk of bias, imprecision
Memory
Memantine vs placebo
no estimate extracted1 study · 23 participantsLow
Downgraded: risk of bias, imprecision
Adaptive behaviour
Memantine vs placebo
no estimate extracted1 study · 23 participantsLow
Downgraded: risk of bias, imprecision
Hyperactivity
Memantine vs placebo
no estimate extracted1 study · 121 participantsLow
Downgraded: risk of bias, imprecision
Irritability
Memantine vs placebo
no estimate extracted1 study · 121 participantsLow
Downgraded: risk of bias, imprecision